SCM
NVO

Segantii Capital Management’s Novo Nordisk NVO Stock Holding History

Segantii Capital Management’s Portfolio NVO Stock Details NVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-75,000
Closed -$6.86M – 164
2023
Q3 		$6.86M Buy
+75,000
New +$6.61M 0.24% 55

Other funds holding NVO

Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Fayez Sarofim & Co
Fayez Sarofim & Co Houston, Texas $39.1B AUM 15.14% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
F
Folketrygdfondet Oslo Norway, Norway $5.64B AUM 47.16% 1-Year Est. Return
Polen Capital Management
Polen Capital Management Boca Raton, Florida $11.6B AUM 8.03% 1-Year Est. Return

Segantii Capital Management's NVO Position: Q4 2023 in Review

Segantii Capital Management sold out of Novo Nordisk (NVO) in Q4 2023, closing a stake of 75,000 shares — an estimated $6.86M sold.

Segantii Capital Management first reported a position in NVO in Q3 2023 and held it in 1 quarter. The position peaked at $6.86M in Q3 2023. 1,513 funds tracked by Wall St. Rank hold NVO as of Q4 2023.

  • Segantii Capital Management reported no remaining Novo Nordisk position as of Q4 2023 after selling out during the quarter.
  • Segantii Capital Management sold 75,000 Novo Nordisk shares in Q4 2023, an estimated $6.86M.
  • Segantii Capital Management first reported a position in Novo Nordisk in Q3 2023 and held it in 1 quarter.
  • Segantii Capital Management's Novo Nordisk position peaked at $6.86M in Q3 2023.
  • 1,513 funds tracked by Wall St. Rank held Novo Nordisk as of Q4 2023.

Based on Segantii Capital Management's 13F filing for Q4 2023, filed 7 Feb 2024.